低剂量CT筛查的改进导致早期NSCLC诊断增加，而手术切除——通常为肺叶切除术或肺段切除术——仍是主要的治愈性选择。然而在香港，患者经常伴有慢性呼吸系统疾病或心血管问题等共病，因此保留健康肺组织对其长期生活质量至关重要。
适应症：Lung Cancer (NSCLC)
入组条件
纳入标准
- Age ≥18 years
- Histologically or cytologically confirmed stage IA NSCLC (T1N0M0, tumor ≤3 cm)
- Scheduled for surgical treatment (segmentectomy or lobectomy or robotic/navigation-guided bronchoscopic ablation)
- Ability to complete postoperative visits for up to 2 years
- Provided informed consent
排除标准
- Presence of lymph node involvement (N1 or higher) or distant metastases (M1)
- Concomitant primary malignancies that could confound outcome analysis
- Insufficient or missing key data points (e.g., tumor size, treatment type, survival status)
- Duplicate or overlapping records from different data sources
- Contraindications to anesthesia or sedation for bronchoscopy or surgery
- Inability or unwillingness to perform the PF tests
- Pregnant or breastfeeding women (for prospective phase)
- Inability or unwillingness to comply with study procedures
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。